Does Propofol Help With Pain? A Sedative, Not an Analgesic

Propofol is not a pain reliever. It is a sedative-hypnotic that produces sleep and amnesia, and it is neither approved nor used as an analgesic — which is why patients sedated with propofol still receive a separate drug to control pain.¹ That single distinction explains almost every confusing thing written about this drug: propofol can make a person stop reporting pain without doing much to the pain itself.

Sedation and analgesia are two different drug effects

Anesthesia is not one effect. It is a bundle of separate effects that different drugs produce to different degrees: unconsciousness, amnesia, muscle relaxation, suppression of reflexes, and analgesia. A drug can deliver some of them and not others. Propofol is weighted toward the first two. Its labeling is candid that the mechanism, like that of all general anesthetics, is poorly understood, but propofol is thought to produce its sedative effects by positively modulating the inhibitory neurotransmitter GABA at the GABA-A receptor.¹ Turning up inhibition broadly quiets cortical activity, producing sedation and then unconsciousness. It does not specifically interrupt the nociceptive pathways carrying a pain signal from tissue to spinal cord to brain. Opioids act on opioid receptors in those pathways. Local anesthetics block sodium channels in the nerve itself. Propofol does neither.

The FDA-approved labeling reflects this. Propofol’s indications are induction and maintenance of general anesthesia, monitored anesthesia care sedation, sedation alongside regional anesthesia, and ICU sedation of intubated, mechanically ventilated adults. Pain is not among them.¹

The ICU data make the point better than any argument

The clearest evidence sits inside the drug’s own label. In the studies supporting propofol for ICU sedation, patients were sedated continuously, sometimes for days. The label records that although there were reports of reduced analgesic requirements, most patients still received opioids for analgesia during maintenance of sedation, with morphine or fentanyl given as needed.¹

That sentence is the practical answer to the question, and it is worth quoting in full rather than trimming. Propofol may lower how much analgesic a deeply sedated patient needs. It did not replace one. The label separately notes that the propofol dose required may fall when pain is adequately managed with analgesic agents¹ — the relationship running in both directions, which is what you expect from two drugs doing different jobs, not from one drug doing both.

What propofol does to pain perception is genuinely unsettled

The experimental literature does not agree with itself, and it is worth being honest about that rather than picking the flattering study. A 1991 study enrolled nineteen subjects, twelve of whom received subhypnotic doses of propofol and thiopental while seven received saline. In those receiving drug, both agents raised the pain threshold to argon laser stimulation and reduced the amplitude of the pain-evoked potential.² Read alone, that looks like analgesia.

A better-controlled 2005 crossover study pointed the opposite way. Eighteen subjects received propofol by target-controlled infusion at two sedative concentrations and rated heat stimuli on a visual analog scale. Pain intensity ratings rose from 28/100 on placebo to 35/100 with mild sedation and 40/100 with moderate sedation, and unpleasantness rose in parallel. The authors called the effect unexpected and concluded that it highlights the need for adequate analgesia in sedated patients.³

Sedated patients look comfortable. Their self-reported pain in that experiment got worse. A treatment that changes how a person reports or remembers pain is not a treatment that reduces it — the same distinction that matters in opioid-induced hyperalgesia.

Where the real research interest is: refractory headache

Propofol’s pain literature is not about chronic pain generally. It is almost entirely about aborting severe headache attacks that have failed everything else. The interest began with an uncontrolled 2000 report from an outpatient headache clinic, in which 77 patients with intractable headache received subanesthetic intravenous propofol averaging 110 mg. The average reported reduction in headache intensity was 95.4%, with 63 of 77 reporting complete abolition.⁴ Striking numbers — and exactly the kind of uncontrolled result that shrinks under blinding.

It did shrink. A 2018 randomized trial in 66 pediatric patients found no advantage for low-dose propofol over standard therapy in pain reduction, 51% versus 59%, though propofol was associated with fewer rebound headaches at 24 hours, 25.0% versus 66.7%.⁵ A 2021 double-blind trial compared propofol with a matching intralipid placebo in 40 adults with acute migraine. Propofol was not superior for the primary outcome of headache resolution at one hour, 24% versus 32%, though it did beat placebo on a secondary outcome, a two-point or greater drop in pain score, 81% versus 37%.⁶

A 2020 systematic review of nine studies and 290 patients concluded that propofol may be an effective rescue therapy for acute migraine in the emergency department, but that its place in therapy is unknown given dosing variation and small samples, and that its safety in this setting has not been adequately examined.⁷ A drug review described it for super-refractory migraine as an off-label option used when conventional drugs fail, noting its narrow therapeutic index, abuse potential, and the absence of adequate double-blind studies substantiating effectiveness.⁸

Two points matter. All of this is emergency or inpatient rescue for an acute attack, not maintenance therapy for chronic pain. And even there, the controlled evidence is thin and mixed. If you live with severe recurring headache, the treatments with real outpatient evidence are a different set entirely, covered on our migraine and headache page and our cluster headache page.

The one chronic-pain signal, and why it went nowhere

A 1995 placebo-controlled, double-blind study gave subhypnotic propofol to 32 patients with non-malignant chronic pain. The authors reported that central pain, meaning pain generated by damage to the brain or spinal cord itself, was at least partially controlled, while neuropathic pain was not, and suggested propofol might be useful diagnostically in unclear cases.⁹

That was thirty years ago, in 32 patients, and it did not become a treatment. A finding that interesting failing to reach practice over three decades is itself informative.

The HCN1 discovery is real, and it is not a pain result

A 2024 study in Nature used cryo-electron microscopy and electrophysiology to show that propofol inhibits the HCN1 channel by binding a groove between two transmembrane helices, and that it restored normal voltage-dependent closing in two HCN1 variants associated with epilepsy.¹⁰ This is elegant structural biology, and it identifies a druggable site.

It is also bench work in cells, testing epilepsy-associated channel variants. It did not treat pain, or patients. A binding site described in a cell line is years and several failure points away from a therapy. This work suggests a target, not a treatment. Nerve-pain conditions driven by channel dysfunction are a different problem with a different mechanism, and are worked up here with electrodiagnostic testing rather than with a sedative.

Why propofol is not an outpatient chronic-pain treatment

Even setting efficacy aside, the delivery requirements rule it out for ongoing use.

• It requires anesthesia-trained personnel. The label directs that for general anesthesia or monitored anesthesia care, propofol be administered only by persons trained in the administration of general anesthesia who are not involved in conducting the procedure.¹
• It requires airway rescue capability on hand. Sedated patients must be continuously monitored, with equipment for maintaining a patent airway, artificial ventilation, supplemental oxygen, and cardiovascular resuscitation immediately available.¹
• There is little safety margin. Propofol has a narrow therapeutic index.⁸ Apnea requiring ventilatory support often occurs during induction and may persist beyond 60 seconds, and dose requirements vary between people.¹
• It is misused, with high lethality. A survey of all 126 US academic anesthesiology programs, with a 100% response rate, found 18% reported propofol abuse or diversion in the prior decade. Of 25 individuals identified, 7 died, and 71% of programs had no system to control or monitor propofol stocks.¹¹
• The drug itself hurts. Pain and burning at the injection site are recognized adverse reactions,¹ common enough that a body of randomized trials exists purely on preventing it.¹²

A treatment for a long-term condition has to be safely repeatable. A drug needing an anesthesia provider and resuscitation equipment for every dose is not.

What actually treats refractory pain

The reason people search for propofol is usually not propofol. It is that standard treatment has not worked and they want something stronger. That is a reasonable place to be, and it has better answers.

Interventional pain medicine works by interrupting or modulating a specific pain generator rather than sedating the whole brain. Depending on what drives the pain, that can mean a diagnostic or therapeutic nerve block, a sphenopalatine ganglion block for certain head and facial pain, an epidural steroid injection for compressive spine pain, or spinal cord stimulation when pain persists despite other treatment.

There is also one anesthetic that genuinely does have analgesic properties, and it is not propofol. Ketamine acts at the NMDA receptor, which sits directly in the pathway maintaining central sensitization, and is used in pain medicine on that basis, including for complex regional pain syndrome and RSD. Our ketamine therapy page and this overview of how ketamine may help with chronic pain cover the mechanism and the limits.

If you are in the St. Louis area

Padda Institute, Center for Interventional Pain Management, evaluates and treats refractory pain at 4477 Woodson Rd, Suite 100, St. Louis, MO 63134 and at 12174 Natural Bridge Road, Suite 100, St. Louis, MO 63044. Procedures are performed under local anesthesia rather than general anesthesia or sedation, so patients stay awake and can give feedback during treatment. Review the options on our pain treatments page or request an appointment. Call (314) 481-5000.

Frequently asked questions

Does propofol help with pain?

Not directly. Propofol is a sedative-hypnotic, not an analgesic, and sedated patients still receive separate pain medication.¹ It can stop a person responding to or remembering pain, which is not the same thing. For treatments targeting a pain generator rather than consciousness, see our pain treatments overview.

Why do some studies say propofol reduced pain?

A few did, and they were mostly small or uncontrolled. Tested against placebo in a blinded migraine trial, propofol failed its primary outcome,⁶ and a sedation study found pain ratings increased.³ Uncontrolled pain results routinely shrink under blinding, which is why we flag evidence quality on pages like our migraine and headache page.

Is propofol used for chronic pain?

No. Its pain-related use is limited to hospital or emergency rescue treatment of an acute refractory headache attack, and even there the evidence is mixed.⁷ Chronic pain is managed with repeatable outpatient treatments; see the range on our pain treatments page.

Is ketamine different from propofol for pain?

Yes, mechanistically. Ketamine blocks the NMDA receptor, which participates directly in central sensitization, giving it analgesic activity propofol lacks. We cover its uses and limits on our ketamine therapy page and in this article on intranasal ketamine for refractory headaches.

Will I be sedated with propofol for a pain injection?

Not at our practice. Interventional injections are performed with local anesthetic while you stay awake, which preserves your ability to report what you feel during the procedure. Our nerve block page explains how these procedures are done.

Does the 2024 Nature HCN1 study mean propofol will treat pain?

No. That study described where propofol binds on the HCN1 channel and showed it restored normal gating in epilepsy-associated variants in cells.¹⁰ It did not test pain or treat patients. To discuss options that exist today, request an appointment.

Sources

1. DIPRIVAN (propofol) injectable emulsion, USP — full prescribing information. Fresenius Kabi USA, LLC. US Food and Drug Administration / DailyMed. DailyMed label
2. Anker-Møller E, Spangsberg N, Arendt-Nielsen L, Schultz P, Kristensen MS, Bjerring P. Subhypnotic doses of thiopentone and propofol cause analgesia to experimentally induced acute pain. British Journal of Anaesthesia. 1991;66(2):185-8. PMID 1817618
3. Frölich MA, Price DD, Robinson ME, Shuster JJ, Theriaque DW, Heft MW. The effect of propofol on thermal pain perception. Anesthesia & Analgesia. 2005;100(2):481-486. PMID 15673879
4. Krusz JC, Scott V, Belanger J. Intravenous propofol: unique effectiveness in treating intractable migraine. Headache. 2000;40(3):224-30. PMID 10759925
5. Sheridan DC, Hansen ML, Lin AL, Fu R, Meckler GD. Low-dose propofol for pediatric migraine: a prospective, randomized controlled trial. The Journal of Emergency Medicine. 2018;54(5):600-606. PMID 29456086
6. Meek R, Graudins A, McDonald M, McGannon D, Limm E. Comparing propofol with placebo for early resolution of acute migraine in adult emergency department patients: a double-blind randomised controlled trial. Emergency Medicine Australasia. 2021;33(3):465-472. PMID 33070469
7. Piatka C, Beckett RD. Propofol for treatment of acute migraine in the emergency department: a systematic review. Academic Emergency Medicine. 2020;27(2):148-160. PMID 31621134
8. Dhir A. Propofol in the treatment of refractory migraine headaches. Expert Review of Neurotherapeutics. 2016;16(9):1007-11. PMID 27454834
9. Canavero S, Bonicalzi V, Pagni CA, et al. Propofol analgesia in central pain: preliminary clinical observations. Journal of Neurology. 1995;242(9):561-7. PMID 8551317
10. Kim ED, Wu X, Lee S, et al. Propofol rescues voltage-dependent gating of HCN1 channel epilepsy mutants. Nature. 2024;632(8024):451-459. PMID 39085604
11. Wischmeyer PE, Johnson BR, Wilson JE, et al. A survey of propofol abuse in academic anesthesia programs. Anesthesia & Analgesia. 2007;105(4):1066-71. PMID 17898389
12. Wang W, Zhou L, Wu LX, Wang T, Zhang CB, Sun L. 5-HT3 receptor antagonists for propofol injection pain: a meta-analysis of randomized controlled trials. Clinical Drug Investigation. 2016;36(4):243-53. PMID 26860485

Dr. Gurpreet Singh Padda, MD, MBA, MHP